Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 13, 2026

Figure Technology Solutions Announces Preliminary Fourth Quarter & Full Year 2025 Financial Results

View original at globenewswire.com
Figure Technology Solutions Announces Preliminary Fourth Quarter & Full Year 2025 Financial Results NEW YORK, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • More than 200 partners use Figure's loan origination system and capital marketplace.

    80% confidence

  • Figure remains focused on expanding its partner network, deepening marketplace liquidity, and advancing blockchain-native infrastructure.

    80% confidence

  • Figure and its partners have collectively originated over $22 billion of home equity to date, making Figure's ecosystem the largest non-bank provider of home equity financing.

    80% confidence

  • Figure is the market leader in real world asset (RWA) tokenization.

    80% confidence

  • Stock-based compensation expense for Q4 2025 makes up approximately 64% of stock compensation expense for the full year 2025, primarily driven by one-time fully vested grants to third party advisors and graded vesting RSUs.

    80% confidence

  • Q4 2025 strong results reflect meaningful progress in modernizing capital markets and position Figure to further accelerate that transformation.

    80% confidence

  • The preliminary financial results are unaudited and have not been reviewed by the independent registered public accounting firm; results could change materially.

    80% confidence

  • Figure achieved triple-digit year-over-year growth in Consumer Loan Marketplace volume in Q4 2025.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com